Share on StockTwits

Portola Pharmaceuticals (NASDAQ:PTLA) EVP John T. Curnutte sold 30,000 shares of Portola Pharmaceuticals stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $28.33, for a total transaction of $849,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Portola Pharmaceuticals (NASDAQ:PTLA) traded down 1.65% on Thursday, hitting $29.87. The stock had a trading volume of 372,310 shares. Portola Pharmaceuticals has a 52-week low of $19.59 and a 52-week high of $30.95. The stock has a 50-day moving average of $23.31 and a 200-day moving average of $25.04. The company’s market cap is $1.228 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.75) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.72) by $0.03. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.81 million. During the same quarter in the prior year, the company posted ($12.94) earnings per share. The company’s quarterly revenue was down 23.8% on a year-over-year basis. On average, analysts predict that Portola Pharmaceuticals will post $-3.44 earnings per share for the current fiscal year.

Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.